SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suven Life Sciences' Nomination & Remuneration Committee approved the second grant (Grant-II) of 345,000 stock options to eligible employees on May 13, 2025, under the SLSL ESOP 2020 scheme. Each option can be converted into one equity share of face value ₹1 at an exercise price of ₹55 per option. The options will vest in three tranches: 40% in May 2026, 30% in May 2027, and 30% in May 2028, with a two-year exercise window from each vesting date. As of now, no options have been exercised, no money has been realized, and no options have lapsed.
This is a routine employee incentive grant and will lead to mild dilution once exercised. Shareholders should note the potential equity dilution of up to 345,000 shares (face value ₹1 each) over the next 3-5 years, though the impact on share value is limited given the company's larger share base.